Obstructive Sleep Apnea Clinical Trial
Official title:
Effect of Correction of Obstructive Sleep Apnea With Positive Airway Pressure on Central Blood Pressure and Kidney and Endothelial Function
Obstructive sleep apnea (OSA) is a frequently underdiagnosed condition that has emerged as an increasing medical problem with important social and financial implications worldwide. OSA is a well established risk factor for systemic hypertension myocardial infarction or stroke and it has been documented that blood pressure rises in a very consistent fashion during apneic episodes. The incidence of the episodes of apnea during sleep causes repeated subclinical acute kidney injuries (AKI) contributing to the development of CKD. One of the mechanisms responsible for AKI might be endothelial injury followed by an increase of central aortic pressure.
Obstructive sleep apnea (OSA) is a frequently underdiagnosed condition that has emerged as
an increasing medical problem with important social and financial implications worldwide.
Its prevalence may reach 25% in middle-aged men and 11% in women. The most important risk
factor for OSA is obesity - every 10% weight gain increases the incidence of the disease 6
times. OSA usually occurs in middle age males and is characterized by history of snoring,
daytime somnolence and nocturnal choking or gasping. The underlying cause is transient
cessation of airflow due to occlusion of the oropharyngeal tract. Episodes of apnea are
considered important if they persist for longer than 10 seconds, but in some cases they may
last as long as 2 minutes. The airway occlusion results in recurrent hypoxia, hypercapnia,
arousals from sleep, compensatory hyperventilation leading to secondary hypocapnia and
generation of exaggerated negative intrathoracic pressure that all can either directly or
indirectly be harmful to the cardiovascular system through several pathways like sympathetic
activation, inflammation, oxidative stress and endothelial dysfunction. Recurrent episodes
of apnea/hypoxia may negatively affect the function of many organs, e.g. they induce
(cyclical bradycardia during the apneic episodes, followed by tachycardia during the ensuing
ventilatory phases) or rise blood pressure. Moreover, OSA is a well established risk factor
for systemic hypertension myocardial infarction or stroke and it has been documented that
blood pressure rises in a very consistent fashion during apneic episodes. The mechanisms
responsible for this phenomenon are complex because the direct effects of apnea (hypoxemia
and low intrathoracic pressure) are modified by cardiopulmonary reflexes. Undoubtedly, the
rapid increase in arterial pressure that occurs at the end of an apneic episode is mainly
mediated by surges in sympathetic function during the arousal reaction.
Hypertension has emerged as a second, after diabetes mellitus, most frequent cause of
chronic kidney disease (CKD). The rise of arterial blood pressure and endothelial damage due
to ischaemia during apneic episodes may contribute to CKD. According to the recent findings
OSA patients are much more frequently diagnosed with chronic kidney disease. The high
frequency of OSA in patients with renal function impairment could be explained by the fact
that the most common comorbid conditions of CKD, namely atherosclerosis and diabetes, are
also independently associated with his syndrome. The detailed pathogenesis of the strong
relation between OSA and CKD has not been investigated so far.
OSA patients are characterized by arterial stiffness, evaluated by pulse-wave velocity
(PWV). PWV is a sensitive and validated marker of cardiovascular risk, including premature
coronary artery disease, atherosclerosis, stroke and cardiovascular mortality.
The diagnosis of acute kidney injury (AKI) is routinely based on changes in serum
creatinine, but its measurements are a poor indicator of acute deterioration in kidney
function. First, serum creatinine concentrations might not change until about 50% of kidney
function has already been lost. Second, serum creatinine levels can vary widely with age,
sex, muscle mass, muscle metabolism, medications and hydration status. Novel, more specific
and sensitive biomarkers of AKI are neutrophil gelatinase-associated lipocalin (NGAL),
cystatin C, kidney injury molecule 1 (KIM-1), liver-type fatty acid-binding protein
(L-FABP), which concentrations in both urine or serum rise significantly in patients with
AKI and correlate with severity of kidney injury.
CKD is a devastating illness that has reached epidemic proportions worldwide. CKD is
characterized by a progressive decline in kidney function that is associated with excess
morbidity and mortality. The deterioration of kidney function can be delayed and patient
outcome favorably affected if kidney disease is recognized and treated in a timely manner.
In our study we would like to prove that apneic episodes during sleep can cause repeated
renal ischaemia-reperfusion injuries, which may lead to repeated acute subclinical kidney
injuries (AKI) contributing to the development of chronic kidney disease.
The aim of this project is to study the influence of sleep apnea syndrome on the markers of
acute kidney injury, endothelial function, arterial stiffness and central aortic pressure.
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05857384 -
Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs
|
Phase 1 | |
Recruiting |
NCT04547543 -
Follow-up of Apneic Patients by Visio-consultation
|
N/A | |
Recruiting |
NCT05371509 -
Novel Myofunctional Water Bottle to Reduce OSA and Snoring Study
|
N/A | |
Completed |
NCT02515357 -
Mediterranean Diet/Lifestyle Intervention in Obstructive Sleep Apnea
|
N/A | |
Completed |
NCT05582070 -
Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction
|
N/A | |
Active, not recruiting |
NCT03189173 -
Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea
|
Phase 2 | |
Completed |
NCT04084899 -
The Effect of CPAP on Lung Hyperinflation in Patients With OSA
|
||
Completed |
NCT03032029 -
Registry on the Treatment of Central and Complex Sleep-Disordered Breathing With Adaptive Servo-Ventilation
|
||
Recruiting |
NCT04028011 -
Clinical Evaluation of a Wearable Technology for the Diagnosis of Sleep Apnoea
|
||
Recruiting |
NCT06047353 -
Community Health Advocates for Motivating PAP Use in Our Neighborhoods.
|
N/A | |
Completed |
NCT05253963 -
Acute Effect of CPAP on Weight in Patients With Obstructive Sleep Apnea
|
N/A | |
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Completed |
NCT03589417 -
Postural Stability, Balance and Fall Risk in Patients With Obstructive Sleep Apnea
|
||
Recruiting |
NCT04335994 -
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
|
N/A | |
Withdrawn |
NCT04063436 -
Evaluation of a New Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea
|
N/A | |
Recruiting |
NCT05385302 -
Sociological Determinants of Positive Airway Pressure Adherence in OSA Patients
|
||
Recruiting |
NCT04572269 -
Metabolomics of Obstructive Sleep Apnea
|
||
Not yet recruiting |
NCT06467682 -
12-week Tele-exercise Program in Patients With OSA
|
N/A | |
Withdrawn |
NCT04011358 -
Retinal Vein Occlusion and Obstructive Sleep Apnea: A Case Control Study
|
N/A |